{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:38:10Z","timestamp":1783528690375,"version":"3.55.0"},"reference-count":50,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.3960\/jslrt.19013","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T18:05:59Z","timestamp":1561658759000},"page":"56-63","source":"Crossref","is-referenced-by-count":10,"title":["Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype"],"prefix":"10.3960","volume":"59","author":[{"given":"Akira","family":"Satou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of hematopoietic and lymphoid tissue. Revised 4th ed, Lyon, International Agency for Research on Cancer. 2017; pp. 453-464."},{"key":"2","unstructured":"2 Hoshida Y, Xu JX, Fujita S <i>et al.<\/i> Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007; 34: 322-331."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ichikawa A, Arakawa F, Kiyasu J <i>et al.<\/i> Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013; 91: 20-28.","DOI":"10.1111\/ejh.12116"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Mariette X, Cazals-Hatem D, Warszawki J <i>et al.<\/i>. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002; 99: 3909-3915.","DOI":"10.1182\/blood.V99.11.3909"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Yamakawa N, Fujimoto M, Kawabata D <i>et al.<\/i> A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014; 41: 293-299.","DOI":"10.3899\/jrheum.130270"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Satou A, Tabata T, Miyoshi H <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. Mod Pathol. 2019; Epub ahead of print.","DOI":"10.1038\/s41379-019-0264-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kondo S, Tanimoto K, Yamada K <i>et al.<\/i> Mature T\/NK-cell lymphoproliferative disease and Epstein\u2013Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch. 2013; 462: 399-407.","DOI":"10.1007\/s00428-013-1389-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hatanaka K, Nakamura N, Kojima M <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract. 2010; 206: 9-13.","DOI":"10.1016\/j.prp.2009.03.005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ishibuchi H, Motegi S, Yamanaka M, Amano H, Ishikawa O. Methotrexate-associated lymphoproliferative disorder: sequential development of angioimmunoblastic T-cell lymphoma-like lymphoproliferation in the lymph nodes and diffuse large B-cell lymphoma in the skin in the same patient. Eur J Dermatol. 2015; 25: 361-362.","DOI":"10.1684\/ejd.2015.2582"},{"key":"10","unstructured":"10 Claudino WM, Gibson B, Tse W, Krem M, Grewal J. Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review. Am J Blood Res. 2016; 6: 1-5."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Saleh JZ, Lee LH, Schieke SM, Hosking PR, Hwang ST. Methotrexate-induced CD30+ T-cell lymphoproliferative disorder of the oral cavity. JAAD Case Rep. 2016; 2: 354-356.","DOI":"10.1016\/j.jdcr.2016.02.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Koji H, Yazawa T, Nakabayashi K <i>et al.<\/i> CD8-positive T-cell lymphoproliferative disorder associated with Epstein-Barr virus-infected B-cells in a rheumatoid arthritis patient under methotrexate treatment. Mod Rheumatol. 2016; 26: 271-275.","DOI":"10.3109\/14397595.2013.850613"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hatachi S, Kunitomi A, Aozasa K, Yagita M. CD8 + T-cell lymphoproliferative disorder associated with Epstein\u2013Barr virus in a patient with rheumatoid arthritis during methotrexate therapy. Mod Rheumatol. 2010; 20: 500-505.","DOI":"10.3109\/s10165-010-0300-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Takajo I, Umekita K, Ikei Y, Oshima K, Okayama A. Adult T-cell Leukemia\/Lymphoma as a Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis. Intern Med. 2018; 57: 2071-2075.","DOI":"10.2169\/internalmedicine.0308-17"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nemoto Y, Taniguchi A, Kamioka M <i>et al.<\/i> Epstein\u2013Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment. Int J Hematol. 2010; 92: 364-368.","DOI":"10.1007\/s12185-010-0642-5"},{"key":"16","unstructured":"16 Terroso G, Aleixo J, Bernardes M <i>et al.<\/i> Nasal type extranodal NK\/T cell lymphoma diagnosed in a patient with rheumatoid arthritis under methotrexate. Acta Reumatol Port. 2014; 39: 77-81."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Tajima S, Takanashi Y, Koda K, Fukayama M. Methotrexate-associated lymphoproliferative disorder presenting as extranodal NK\/T-cell lymphoma arising in the lungs. Pathol Int. 2015; 65: 661-665.","DOI":"10.1111\/pin.12346"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Gratzinger D, de Jong D, Jaffe ES <i>et al.<\/i> T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting. Am J Clin Pathol. 2017; 147: 188-203.","DOI":"10.1093\/ajcp\/aqw213"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol. 2018; 74: 5-16.","DOI":"10.1016\/j.humpath.2018.01.005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yabe M, Medeiros LJ, Tang G <i>et al.<\/i> Prognostic Factors of Hepatosplenic T-cell Lymphoma. Am J Surg Pathol. 2016; 40: 676-688.","DOI":"10.1097\/PAS.0000000000000614"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn\u2019s Colitis. 2010; 4: 511-522.","DOI":"10.1016\/j.crohns.2010.05.006"},{"key":"22","unstructured":"22 Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010; 28(suppl 61): S52-S57."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000; 88: 497-502.","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Mellemkj\u00e6r L, Linet MS, Gridley G <i>et al.<\/i> Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996; 32: 1753-1757.","DOI":"10.1016\/0959-8049(96)00210-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Gridley G, McLaughlin JK, Ekbom A <i>et al.<\/i> Incidence of cancer among patients with rheumatoid arthritis. JNCI Journal of the National Cancer Institute. 1993; 85: 307-311.","DOI":"10.1093\/jnci\/85.4.307"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Gion Y, Iwaki N, Takata K <i>et al.<\/i> Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017; 108: 1271-1280.","DOI":"10.1111\/cas.13249"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Kamel OW, van de Rijn M, Weiss LM <i>et al.<\/i> Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993; 328: 1317-1321.","DOI":"10.1056\/NEJM199305063281806"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Feng W, Cohen JI, Fischer S <i>et al.<\/i> Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. JNCI Journal of the National Cancer Institute. 2004; 96: 1691-1702.","DOI":"10.1093\/jnci\/djh313"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol. 2005; 49: 285-292.","DOI":"10.1387\/ijdb.041947el"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Masucci MG, Ernberg I. Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol. 1994; 2: 125-130.","DOI":"10.1016\/0966-842X(94)90599-1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Sandhu A, Ahmad S, Kaur P <i>et al.<\/i> Methotrexate preferentially affects Tc1 and Tc17 subset of CD8 T lymphocytes. Clin Rheumatol. 2019; 38: 37-44.","DOI":"10.1007\/s10067-018-4011-8"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Farcet JP, Gaulard P, Marolleau JP <i>et al.<\/i> Hepatosplenic T-cell lymphoma: sinusal\/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood. 1990; 75: 2213-2219.","DOI":"10.1182\/blood.V75.11.2213.2213"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Macon WR, Levy NB, Kurtin PJ <i>et al.<\/i> Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol. 2001; 25: 285-296.","DOI":"10.1097\/00000478-200103000-00002"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Herrinton LJ, Liu L, Weng X <i>et al.<\/i> Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011; 106: 2146-2153.","DOI":"10.1038\/ajg.2011.283"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Mackey AC, Green L, Liang L, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44: 265-267.","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009; 48: 386-388.","DOI":"10.1097\/MPG.0b013e3181957a11"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Deepak P, Sifuentes H, Sherid M <i>et al.<\/i> T-cell non-Hodgkin\u2019s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-\u03b1) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013; 108: 99-105.","DOI":"10.1038\/ajg.2012.334"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Kotlyar DS, Osterman MT, Diamond RH <i>et al.<\/i> A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 36-41.e1.","DOI":"10.1016\/j.cgh.2010.09.016"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Navarro JT, Ribera JM, Mate JL <i>et al.<\/i> Hepatosplenic T-gammadelta lymphoma in a patient with Crohn\u2019s disease treated with azathioprine. Leuk Lymphoma. 2003; 44: 531-533.","DOI":"10.1080\/1042819021000035662"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Mittal S, Milner BJ, Johnston PW, Culligan DJ. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to Fludarabine and Alemtuzumab. Eur J Haematol. 2006; 76: 531-534.","DOI":"10.1111\/j.1600-0609.2006.00646.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn\u2019s disease who received infliximab therapy. Leuk Lymphoma. 2007; 48: 1410-1413.","DOI":"10.1080\/10428190701345433"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Humphreys MR, Cino M, Quirt I, Barth D, Kukreti V. Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon- alpha. Leuk Lymphoma. 2008; 49: 1420-1423.","DOI":"10.1080\/10428190802087488"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44 Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn\u2019s disease: case report and literature review. Clin Lymphoma Myeloma Leuk. 2010; 10: 144-148.","DOI":"10.3816\/CLML.2010.n.021"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45 C\u00f4t\u00e9-Daigneault J, Bernard EJ. Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn\u2019s disease: a case report and literature review. Can J Gastroenterol. 2011; 25: 417-418.","DOI":"10.1155\/2011\/148927"},{"key":"45","doi-asserted-by":"crossref","unstructured":"47 Subramaniam K, Yeung D, Grimpen F <i>et al.<\/i> Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014; 44: 287-290.","DOI":"10.1111\/imj.12363"},{"key":"46","doi-asserted-by":"crossref","unstructured":"48 Voss MH, Lunning MA, Maragulia JC <i>et al.<\/i> Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk. 2013; 13: 8-14.","DOI":"10.1016\/j.clml.2012.09.002"},{"key":"47","doi-asserted-by":"crossref","unstructured":"49 Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-\u03b1 inhibitor therapy. Eur J Gastroenterol Hepatol. 2011; 23: 1150-1156.","DOI":"10.1097\/MEG.0b013e32834bb90a"},{"key":"48","doi-asserted-by":"crossref","unstructured":"50 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015; 21: 674-698.","DOI":"10.1097\/MIB.0000000000000243"},{"key":"49","doi-asserted-by":"crossref","unstructured":"51 Tanase A, Schmitz N, Stein H <i>et al.<\/i>. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia. 2015; 29: 686-688.","DOI":"10.1038\/leu.2014.280"},{"key":"50","doi-asserted-by":"crossref","unstructured":"52 Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J. 2015; 5: e318.","DOI":"10.1038\/bcj.2015.43"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/2\/59_19013\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T02:05:43Z","timestamp":1575165943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/2\/59_19013\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.19013","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}